By vgreene, 22 October, 2020 Median time to viral clearance shorter in FPV pts 4 days vs 11 days no difference in chest CT improvement rates on day 4 and 8 but higher rates seen in FPV pts on day 14 91 vs 62 higher CT improvement rates also assoc w pts w
By vgreene, 22 October, 2020 Open label non randomized before after controlled study 80 pts median age 47y w confirmed COVID 19 received either FPV 1 600 mg bid x2 doses then 600 mg bid n 35 or LPV r 400 mg 100 mg bid n 45 for up to 14 days or until viral clearance pts excl if 7 days
By vgreene, 22 October, 2020 Experimental Treatment With Favipiravir for COVID 19 An Open Label Control Study
By vgreene, 22 October, 2020 Study considerations active control more severe critical pts in FPV group pts received other antivirals and traditional Chinese medicine limited observation time frame
By vgreene, 22 October, 2020 No significant difference in primary endpoint of clinical recovery rate on day 7 61 FPV 51 umifenovir quicker defervescence and sx relief w FPV in pts w moderate dz no difference in rate of auxiliary O2 tx or noninvasive mechanical ventilation higher seru
By vgreene, 22 October, 2020 Not currently available in the U S Used in Japan for tx of influenza First approved drug in China for tx of COVID 19
